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Brief Report
An U n u s u a l Reaction to Opioid Blockade
with Naltrexone in a Case of
Post-Traumatic Stress Disorder
Paloma Ibarra 1,2 Stephen P. Bruehl, 1,2 J a m e s A. McCubbin, 1,4
Charles R. Carlson, 2 John F. Wilson, I Jane A. Norton, 1
and T h o m a s B. M o n t g o m e r y 3

An unusual behavioral and cardiovascular reaction was observed during opioid
blockade with naltrexone in a 32-year-old male who met DSM III-R criteria
f o r p o s t - t r a u m a t i c stress disorder (PTSD). A s part o f an ongoing
placebo-controlled investigation of the effects of naltrexone on laboratory and
ambulatory blood pressure reactivity, this participant reported experiencing
feelings of rage, explosive behavior, and other unpleasant symptoms. When
compared to all other subjects (N = 24), this individual showed significantly
greater effects of naltrexone on blood pressure reactivity during the laboratory
stressor. His ambulatory blood pressures, when compared to placebo, were
significantly increased during the 24-hr period following naltrexone. The
unusual behavioral and cardiovascular responses following ingestion o f
naltrexone suggest an important role for endogenous opioids in adjustment to
stress in this case of PTSD.
KEY WORDS: post-traumatic stress disorder; endogenous opioids; ambulatory blood pressure;
naltrexone; laboratory stress.
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INTRODUCTION
Post-traumatic stress disorder (FIND) is a psychophysiologic disturbance
that may arise following exposure to a traumatic event outside the range of
usual human experience (American Psychiatric Association, 1987). Some of
the characteristic symptoms of PTSD include, among others, reexperiencing
the traumatic event(s), numbing of general responsiveness, periodic outbursts
of anger, and increased arousal. Endogenous opioid peptides are released during intense stimulation and may be important in acute and chronic adaptation
to traumatic stress (McCubbin, 1993). Van der Kolk and colleagues (1985)
suggest that these neuropeptide systems may play a role in the development
and maintenance of some of the characteristic symptoms of PTSD.
Evidence of opioidergic mechanisms in PTSD derive from several
lines of research. For example, animal studies indicate that inescapable
stress produces several symptoms that resemble the pathologic profile of
PTSD, including analgesia, hyperarousal, and decreased motivation (Van
der Kolk et al., 1985). Moreover, pharmacologic blockade of endogenous
opioid receptors prevents stress-induced analgesia as well as the performance deficits that typically follow exposure to inescapable stress in rats
(McCubbin et al., 1984). Similar effects have been observed in normal human subjects experiencing a perceived uncontrollable stressor (Bandura
et al., 1988). Recently, the link between opioids and PTSD has been more
directly examined by administration of naloxone to combat veterans with
PTSD (Pitman et al., 1990). Combat veterans with PTSD showed decreased
pain sensitivity following exposure to a dramatized combat movie. These
analgesic effects were blocked with the short-term opioid antagonist naloxone, supporting the notion that endogenous opioids may be directly
involved in the expression of FFSD symptomatology.
Our laboratory has been systematically examining the role of opioids
in the expression of individual differences in circulatory, neuroendocrine,
and behavioral reactivity to stress in young adults (McCubbin et al., 1985;
McCubbin et al., 1989). Using pharmacologic blockade of endogenous
opioids with naloxone, these studies have suggested that opioids can inhibit
cardiovascular, sympathoadrenomedullary, and pituitary-adrenocortical reactivity, and moreover, this opioidergic inhibitory mechanism is diminished
in persons at risk for cardiovascular disease. This research has recently been
expanded to studies of the effect of the long-lasting oral opioid antagonist,
naltrexone, on laboratory reactivity (McCubbin et al., 1992) and 24-hr ambulatory blood pressure patterns. We now report a case of an unusual
behavioral and cardiovascular reaction during opioid blockade with naltrexone
in a young adult male with a history of childhood abuse and military combat
trauma who met DSM III-R criteria for PTSD.
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METHODS

The present case study resulted from a reaction to opioid blockade
in one individual participating in a single-blind placebo-controlled investigation of laboratory and ambulatory stress. Twenty-four subjects with
mildly elevated blood pressures were recruited from an on-campus screening similar to that described in McCubbin et al. (1985). Male young adult
volunteers with stable mean arterial pressures in the upper quintile of the
distribution were scheduled for four in-laboratory psychological stress
tests. Because of a related interest in ambulatory pressures, the long lasting, oral opioid blocking drug naltrexone (Trexan, DuPont) was used. In
the laboratory, subjects were fitted with an automated blood pressure cuff
(Critikon, Tampa), and following a 10-min rest, blood pressures and heart
rates were obtained. Subjects were then given either a 50 mg naltrexone
tablet or a placebo (order was counterbalanced). Subjects rested for one
hour and were then reinstrumented for blood pressure measurement.
After a 10-min postdrug rest, participants then performed a difficult tenminute arithmetic task (McCubbin et al., 1992), followed by a post stress
recovery period. After the in-lab study, subjects were equipped with a
Spacelabs 90202 ambulatory blood pressure monitor (Spacelabs Inc.,
Redmond, WA) and a diary for a 24-hr study during normal activity. Drug
or placebo within-subject control experiments were scheduled about a
week later. The protocol was approved by the University of Kentucky
Medical Institutional Review Board and participants gave informed consent for the experimental protocol.

RESULTS
A 32-year-old male (Mr. B) reported an unusual set of reactions following his second laboratory session, during which he had blindly received
an oral 50 mg naltrexone tablet. Mr. B had received a placebo tablet during his initial visit to the laboratory, and that laboratory and ambulatory
experience was unremarkable. Approximately one week later, Mr. B returned to the laboratory, received 50 mg naltrexone at 2:30 pm, and participated in the laboratory session. At a b o u t 4:15 pm, Mr. B was
instrumented for ambulatory monitoring, requested to record his activities
and to return the equipment 24 hr later. Upon return to the laboratory
the following day, Mr. B indicated that he had experienced some unusual
symptoms. He was then referred for extended debriefing and psychological
evaluation.
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The following events and symptoms were reported by Mr. B during
debriefing. Approximately 2 hr after administration of naltrexone, Mr. B left
the laboratory and drove to visit his wife at a local business where they were
both employed. On the way, he reported becoming aware that he was getting
a headache and felt that something was "not quite right" with his visual perception. The onset of these symptoms was reported to be gradual.
Upon arrival, he told his wife about his symptoms. As he was looking
at her, he felt he was losing his depth perception; that is, he experience d
the image of his wife as two-dimensional, like "an image on a mirror." He
also experienced the image of his wife as somewhat distorted, which he described as similar to looking through a "carnival mirror." Furthermore, he
noted difficulties focusing, and that his vision appeared to be "skewed" to
his right. According to Mr. B, his wife was amused by the explanation of
his symptoms and began to jokingly move her head from side to side. This
made him "very upset" and as a result he "grabbed" her and told her "don't
do that anymore." Subsequently, he noticed the owner watching him "with
a strange look." Mr. B then became angrier and accused his wife of not
caring that he had a headache and not "paying attention" to him. At that
point, he angrily knocked down several boxes. He then noticed his headache
was dissipating and his visual distortions had disappeared though he remained angry. His wife proceeded back to the stockroom where he followed
her while enraged "at her behavior." Shortly after, he returned to the front
of the store attempting to understand the source of his rage when he observed his ambulatory blood pressure cuff on the floor. He believes he took
it off and dropped it while arguing with his wife. Subsequently, he left the
store, sat in his car, and replaced his blood pressure cuff. While in the car,
he noted that his anger was "turned off like a faucet." He then returned
home and reported no further sequelae.
Mr. B indicated that his behavior had been "very mean, yelling and
screaming past the point of rage." He denied other incidents of similar
behavior without significant provocation. He later reported that his angry
response was totally out of proportion to what had occurred. Furthermore,
he perceived his reaction as a loss of control which was both unfamiliar
and disturbing. Mr. B denied taking alcohol or other drugs. He attributed
his symptoms and his behavior to possible intake of naltrexone.

Case History and Diagnosis
Mr. B was reportedly diagnosed with dyslexia during the second
grade, placed in special education classes, and was prescribed Valium for
"hyperactivity." He reported that he and his 2 siblings were repeatedly

Hosted in the Center for Research on Violence Against Women institutional repository with written permission from John Wiley & Sons, Inc.

Brief Report

307

physically abused in childhood, including beatings, being locked in a closet
for extended periods, and threats to his life. He reported suicidal ideation
following these experiences.
Mr. B enlisted in the Army following his high school graduation and
remained in active service until shortly after his participation in a combat
mission. H e indicated that during the mission he was almost shot and that
he killed one person to save a friend. He said that he had not resolved
his own feelings about having taken someone's life.
Mr. B met the DSM-III-R (American Psychiatric Association, 1987)
criteria for the diagnosis of PTSD. His history of parental abuse, and his
experiences in combat represent events that are, in our judgment, outside
the range of normal human experience. He presented with the following
symptoms: persistent arousal, hypervigilance, intrusive recollections and
nightmares, exaggerated startle responses to innocuous environmental stimuli, a v o i d a n c e of thoughts associated with his traumas, difficulty
remembering aspects of these events, identification with other victims of
trauma, detachment from significant others, and a sense of foreshortened
future.

Cardiovascular Data

Mr. B's resting diastolic pressures in the laboratory prior to administration of naltrexone were not significantly different from the group average (Mr. B = 73.6 mm Hg versus group mean = 75 + 3.41 SD). In
contrast, however, his resting in-lab systolic pressure was significantly
lower than the group average (Mr. B = 108 mm Hg versus group average
123.2 + 7.25, z = 2.10, p < 0.05). Mr. B's blood pressure responses to
arithmetic stress were not different from the group average following placebo administration.
Administration of naltrexone did not significantly affect his resting
pressures in the laboratory. However, naltrexone produced increases in
blood pressure reactivity during and after stress and these effects were significantly greater than the group averages. For example, the drug effect on
Mr. B's diastolic reactivity was significantly greater than the group average
in the second 5 minute block of arithmetic stress (z = 2.53, p < 0.025)
and during both the first (z = 3.04, p = 0.0025) and second (z -- 2.23,
p < 0.05) five-minute blocks of recovery from stress. Naltrexone also increased Mr. B's ambulatory blood pressures during the 24-hr period
immediately following his laboratory sessions. For example, his 24-hr average ambulatory blood pressures were 123/73 mm Hg following placebo, and
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130/80 following naltrexone (t(36) = 5.83, p < 0.001 for systolic, t(36) =
6.21, p < 0.001 for diastolic). There were also effects of naltrexone on
acute ambulatory pressor responses. While there were no systolic readings
above 140 mm Hg during the placebo period, 22.7% of systolic readings
were above 140 mm Hg during the naltrexone period. For ambulatory diastolic pressures, 6.7% of readings were above 90 mm Hg during the placebo
period, but 18.2% of diastolic readings were above 90 mm Hg during the
naltrexone period.

DISCUSSION
The present case study demonstrates an unusual reaction to pharmacologic blockade of opioid receptors with naltrexone in a case of posttraumatic stress disorder. Data from an extensive clinical evaluation
indicates that Mr. B clearly met the DSM III-R criteria for PTSD and
he acknowledged this diagnosis. He added that he had not previously
sought treatment of his disorder for fear of being stigmatized and had
underreported the severity of his symptoms to military personnel and to
counselors.
If endogenous opioids are important in adaptation to repeated
trauma, then it is possible that blockade of these adaptive mechanisms
could precipitate significant psychological distress. In the present case,
naltrexone administration evoked hypervigilance and anger outbursts,
both of these symptoms are included in the DSM-III-R (American Psychiatric Press, 1987) criteria for PTSD. The relationship between opioids
and other unusual symptoms such as dissociative phenomena requires
further investigation. Mr. B's reported history of developmental hyperactivity and dyslexia could not be confirmed. It remains unknown
whether the history of these disorders contributed to Mr. B's reaction
to naltrexone.
Some of the symptoms of PTSD may reflect underlying psychobiologic
mechanisms similar to exogenous opiate withdrawal phenomena (Van der
Kolk et al., 1985). Pharmacologic opioid blockade can precipitate withdrawal in opiate dependency, and the present case could reflect similar
endogenous phenomena. Exaggerated blood pressure reactivity is also typical of opiate withdrawal, further strengthening the conceptual similarities
between the present results, exogenous opiate withdrawal, and PTSD.
Moreover, the antihypertensive medication clonidine eases opiate withdrawal symptoms and may also be effective in t r e a t m e n t of PTSD
hyperreactivity (Gold et al., 1978; Kolb et al., 1984).
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While the present case study results cannot be definitively ascribed
to administration of naltrexone, both the blood pressure and behavioral
responses following ingestion of naltrexone are consistent with a role of
endogenous opioids in acute and chronic adjustment to stress in this case
of PTSD. Therefore, more research is needed on the role of endogenous
opioids in PTSD, hut it is also recommended that opioid receptor blockade,
especially with naltrexone, be utilized with caution in persons with a history
of trauma.
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